Abstract | BACKGROUND: OBJECTIVE: MATERIALS AND METHODS: Of the 40 patients initially enrolled, 34 patients with at least 68 verruca vulgaris (one pair for each subject) completed the study. The selected warts were randomized into two treatment groups, with one wart on each patient receiving intralesional 5-FU+LE (4 mL of 50 mg/mL 5-fluorouracil and 1 mL of a mixture of 20 mg/mL [2%] lidocaine and 0.0125 mg/mL epinephrine) and the other receiving intralesional normal saline placebo using a Mantoux needle. Patients received up to four injections at weekly intervals and were followed at 1 and 6 months after the initial injection. RESULTS: Complete response was observed in 64.7% of the warts treated with 5-FU+LE compared to 35.3% in the warts treated with placebo (p<.05). Systemic reaction or treatment-related adverse medical events and recurrence rate did not differ significantly between two groups. CONCLUSION: The results show that intralesional 5-FU+LE is a safe and effective approach for common warts with high success rate.
|
Authors | Ameneh Yazdanfar, Mahmood Farshchian, Morteza Fereydoonnejad, Mehdi Farshchian |
Journal | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
(Dermatol Surg)
Vol. 34
Issue 5
Pg. 656-9
(May 2008)
ISSN: 1524-4725 [Electronic] United States |
PMID | 18261100
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antimetabolites
- Lidocaine
- Fluorouracil
- Epinephrine
|
Topics |
- Adolescent
- Adult
- Antimetabolites
(administration & dosage)
- Double-Blind Method
- Drug Therapy, Combination
- Epinephrine
(administration & dosage)
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Injections, Intralesional
- Lidocaine
(administration & dosage)
- Male
- Prospective Studies
- Treatment Outcome
- Warts
(drug therapy)
|